tbuckley/cabot-search huggingface dataset:
DNA damage response, a double-edged sword for vascular aging
Authors: Xiao Zhang, Qing Zhao, Tao Wang, Qilin Long, Yixin Sun, Liqun Jiao, Monika Gullerova
Journal: Ageing Research Reviews (2023)

Vascular aging is a major risk factor for age-related cardiovascular diseases, which have high rates of morbidity and mortality. It is characterized by changes in the blood vessels, such as macroscopically increased vascular diameter and intima-medial thickness, chronic inflammation, vascular calcification, arterial stiffening, and atherosclerosis. DNA damage and the subsequent various DNA damage response (DDR) pathways are important causative factors of vascular aging. Deficient DDR, which may result in the accumulation of unrepaired damaged DNA or mutations, can lead to vascular aging. On the other hand, over-activation of some DDR proteins, such as poly (ADP ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM), also can enhance the process of vascular aging, suggesting that DDR can have both positive and negative effects on vascular aging. Despite the evidence reviewed in this paper, the role of DDR in vascular aging and potential therapeutic targets remain poorly understood and require further investigation.
Evaluation of novel candidate filtration markers from a global metabolomic discovery for glomerular filtration rate estimation
Authors: Nora F. Fino, Ogechi M. Adingwupu, Josef Coresh, Tom Greene, Ben Haaland, Michael G. Shlipak, Veronica T. Costa e Silva, Roberto Kalil, Ayse L. Mindikoglu, Susan L. Furth, Jesse C. Seegmiller, Andrew S. Levey, Lesley A. Inker
Journal: Kidney International (2023)
Circulating arginine metabolites in Alzheimer’s disease and vascular dementia: A systematic review and meta-analysis
Authors: Angelo Zinellu, Sara Tommasi, Stefania Sedda, Arduino A. Mangoni
Journal: Ageing Research Reviews (2023)

Alterations in nitric oxide (NO) synthesis have been reported in Alzheimer's disease and vascular dementia. However, as the measurement of NO in biological samples is analytically challenging, alternative, stable circulatory biomarkers of NO synthesis may be useful to unravel new pathophysiological mechanisms and treatment targets in dementia.
A commentary on ‘Clinical evaluation of the first semi-active total knee arthroplasty assisting robot made in China: a retrospective propensity score-matched cohort study’
Authors: Xufeng Wan, Jian Cao, Zongke Zhou
Journal: International Journal of Surgery (2023)

We were highly interested in the article entitled 'Clinical evaluation of the first semi-active total knee arthroplasty assisting robot made in China: a retrospective propensity score-matched cohort study' by Yang et al. The authors aim to conduct the postoperative prosthesis position and clinical functions of the semi-active total knee arthroplasty assisting robot (RATKA) using a 1:2 propensity score matching. However, we came across what we believed were flaws in the study methodology and results about the prothesis and tourniquet, and we would like to discuss them with the authors in conjunction with our own research.
A novel remnant liver-first strategy for liver autotransplantation in patients with end-stage hepatic alveolar echinococcosis: a retrospective case series
Authors: Tao Lv, Gang Xu, Xi Xu, Gang Wu, Chen-Fei Wan, Jiu-Lin Song, Jian Yang, Yong-Jie Zhou, Kui Luo, Hong Wu, Cheng-Jie Ye, Lv-Nan Yan, Wan-Yee Lau, Jia-Yin Yang
Journal: International Journal of Surgery (2023)

Ex vivo liver resection combined with autotransplantation is an effective therapeutic strategy for unresectable end-stage hepatic alveolar echinococcosis (HAE). However, ex vivo liver resection combined with autotransplantation is a technically demanding and time-consuming procedure associated with significant morbidity and mortality. The authors aimed to present our novel remnant liver-first strategy of in vivo liver resection combined with autotransplantation (IRAT) technique for treating patients with end-stage HAE.This retrospective study included patients who underwent IRAT between January 2014 and December 2020 at two institutions. Patients with end-stage HAE were carefully assessed for IRAT by a multidisciplinary team. The safety, feasibility, and outcomes of this novel technique were analyzed.IRAT was successfully performed in six patients, with no perioperative deaths. The median operative time was 537.5 min (range, 501.3-580.0), the median anhepatic time was 59.0 min (range, 54.0-65.5), and the median cold ischemia time was 165.0 min (range, 153.8-201.5). The median intraoperative blood loss was 700.0 ml (range, 475.0-950.0). In-hospital complications occurred in two patients. No Clavien-Dindo grade III or higher complications were observed. At a median follow-up of 18.6 months (range, 15.4-76.0) , all patients were alive. No recurrence of HAE was observed.The remnant liver-first strategy of IRAT is feasible and safe for selected patients with end-stage HAE. The widespread adoption of this novel technique requires further studies to standardize the operative procedure and identify patients who are most likely to benefit from it.
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML
Authors: Bogdan Popescu, Carlos Stahlhut, Theodore C. Tarver, Sydney Wishner, Bianca J. Lee, Cheryl A.C. Peretz, Cuyler Luck, Paul Phojanakong, Juan Antonio Camara Serrano, Henry Hongo, Jose M. Rivera, Simayijiang Xirenayi, John A. Chukinas, Veronica Steri, Sarah K. Tasian, Elliot Stieglitz, Catherine C. Smith
Journal: Cell Reports Medicine (2023)

<h2>Summary</h2> Mutations in the receptor tyrosine kinases (RTKs) FLT3 and KIT are frequent and associated with poor outcomes in acute myeloid leukemia (AML). Although selective FLT3 inhibitors (FLT3i) are clinically effective, remissions are short-lived due to secondary resistance characterized by acquired mutations constitutively activating the RAS/MAPK pathway. Hereby, we report the pre-clinical efficacy of co-targeting SHP2, a critical node in MAPK signaling, and BCL2 in RTK-driven AML. The allosteric SHP2 inhibitor RMC-4550 suppresses proliferation of AML cell lines with FLT3 and KIT mutations, including cell lines with acquired resistance to FLT3i. We demonstrate that pharmacologic SHP2 inhibition unveils an Achilles' heel of RTK-driven AML, increasing apoptotic dependency on BCL2 via MAPK-dependent mechanisms, including upregulation of BMF and downregulation of MCL1. Consequently, RMC-4550 and venetoclax are synergistically lethal in AML cell lines and in clinically relevant xenograft models. Our results provide mechanistic rationale and pre-clinical evidence for co-targeting SHP2 and BCL2 in RTK-driven AML.
Biofunctional coacervate-based artificial protocells with membrane-like and cytoplasm-like structures for the treatment of persistent hyperuricemia
Authors: Qian Hu, Hongbing Lan, Yinmei Tian, Xiaonan Li, Mengmeng Wang, Jiao Zhang, Yulin Yu, Wei Chen, Li Kong, Yuanyuan Guo, Zhiping Zhang
Journal: Journal of Controlled Release (2023)
Microenvironment responsive charge-switchable nanoparticles act on biofilm eradication and virulence inhibition for chronic lung infection treatment
Authors: Pengyu Li, Jieyi Pan, Yating Dong, Yingying Sun, Yalong Wang, Kang Liao, Yili Chen, Xin Deng, Shihui Yu, Haiyan Hu
Journal: Journal of Controlled Release (2023)
DNA tetrahedral nanostructures for the biomedical application and spatial orientation of biomolecules
Authors: Weijun Wang, Mengling Lin, Wenqing Wang, Zhifa Shen, Zai-Sheng Wu
Journal: Bioactive Materials (2023)

DNA not only plays a vital role in nature as fundamental hereditary material for storing genetic material, but also serves as well-defined functional material, for example, building blocks for the assembly of nanoscale bio-architectures by Watson-Crick base-pairing interaction. With the development of molecular biology, biotechnology and nanoscience, structural DNA nanotechnology has achieved numerous advances, contributing to the construction of various DNA nanostructures ranging from discrete objects to one dimensional (1D), two dimensional (2D), and three dimensional (3D) architectures. Among them, DNA tetrahedral nanoarchitecture is intensively studied because of simple 3D structure, easy design and unique properties, such as high rigidity, desirable biostability and efficient cellular uptake without auxiliary species. This review summarizes the research progress in the assembly of DNA tetrahedral objects and outlines the applications in biosensing, drug delivery and targeted therapy. Moreover, the dependence of biological activity of biomolecules on DNA tetrahedron-mediated spatially-controlled arrangement and great potential applications are discussed. In addition, the challenges in the design and clinic applications of DNA tetrahedron-based platforms are described, the perspectives towards biomedical applications are foreseen, and our understandings on further studies of DNA tetrahedron are provided, aiming to motivate the development of DNA nanotechnology and interdisciplinary research.
Uptake of diabetes follow-up checks by minority community groups: a rapid review of the evidence for the CYMELL study
Authors: Llinos Haf Spencer, Mohammed Albustami, Alison Porter, Gargi Naha, Rebecca L Thomas, Siân Rees, Rose Stewart, Thanuja Hettiarachchi, Nicola O’Brien, Rhiannon Tudor Edwards, Ashra Khanom
Journal: The Lancet (2023)
Moderating effect of country-level health determinants on the association between hobby engagement and mental health: cross-cohort multi-level models, meta-analyses, and meta-regressions
Authors: Daisy Fancourt, Taiji Noguchi, Jessica K Bone, Jacques Wels, Qian Gao, Katsunori Kondo, Tami Saito, Hei Wan Mak
Journal: The Lancet (2023)
The Sussex COVID-19 Modelling Cell: the methods and successes of a collaboration between public health teams in local authorities, NHS hospital trusts, NHS commissioners, and universities
Authors: James Van Yperen, Eduard Campillo-Funollet, Anjum Memon, Phil Allman, Jacqueline Clay, Matt Dorey, Graham Evans, Kate Gilchrist, Anotida Madzvamuse
Journal: The Lancet (2023)
Attitudes to long-term care in India: a secondary mixed-methods analysis
Authors: Sweedal Alberts, Abinaya Nadarajah, Claudia Cooper, Bianca Brijnath, Santosh Loganathan, Mathew Varghese, Josefine Antoniades, Upasana Baruah, Briony Dow, Mike Kent, Rachita Rao, Jessica Budgett, Amaani Ahmed
Journal: The Lancet (2023)
Surge of lower respiratory tract group A streptococcal infections in England in winter 2022: epidemiology and clinical profile
Authors: Katie Wrenn, Paula Bianca Blomquist, Carmellie Inzoungou-Massanga, Oluwakemi Olufon, Rebecca L Guy, Diane Hatziioanou, Lucy Findlater, Iona Smith, Mariyam Mirfenderesky, Karen Luyt, Tom Williams, Sylvia Stoianova, Michelle Dickinson, Maaike Pietzsch, Christopher I Jarvis, Colin Brown, Theresa Lamagni, Deepti Kumar
Journal: The Lancet (2023)
Enabling health and maintaining independence for older people at home (HomeHealth trial): a multicentre randomised controlled trial
Authors: Rachael Frost, Christina Avgerinou, Sarah Kalwarowsky, Farah Mahmood, Claire Goodman, Andrew Clegg, Jane Hopkins, Rebecca Gould, Benjamin Gardner, Louise Marston, Rachael Hunter, Kalpa Kharicha, Claudia Cooper, Dawn A Skelton, Vari Drennan, Pip Logan, Kate Walters
Journal: The Lancet (2023)
International evidence on lived experiences of trauma during homelessness and effects on mental health including substance use: a co-produced qualitative systematic review
Authors: Emma A Adams, Maria Raisa Jessica Aquino, Victoria Bartle, Kerry Brennan-Tovey, Joanne Kennedy, Sophie Koehne, Joanne McGrath, Margaret Ogden, Jeff Parker, Steven Thirkle, Eileen Kaner, Sheena E Ramsay
Journal: The Lancet (2023)
Consideration of factors associated with inequalities in interventions that support health-care professionals’ interaction with patients to reduce inappropriate antimicrobial use: a systematic review
Authors: Abimbola Ayorinde, Iman Ghosh, Junaid Shaikh, Victoria Adetunji, Anna Brown, Mary Jordan, Ellie Gilham, Daniel Todkill, Diane Ashiru-Oredope
Journal: The Lancet (2023)
Goal setting as part of a holistic intervention to promote independence in older people with mild frailty: a process evaluation alongside a randomised controlled trial
Authors: Yolanda Barrado-Martín, Rachael Frost, Jessica Catchpole, Tasmin Rookes, Sarah Gibson, Christina Avgerinou, Benjamin Gardner, Rebecca Gould, Paul Chadwick, Claire Jowett, Jane Hopkins, Rashmi Kumar, Rekha Elaswarapu, Louise Marston, Kalpa Kharicha, Vari M Drennan, Kate Walters
Journal: The Lancet (2023)
Perspectives on registration to primary care from inclusion health groups in England: a mixed-method study
Authors: Ada Humphrey, Lucy Fagan, Elspeth Carruthers, Jin-Min Yuan, Kemi Ogunlana, Janet Alfred, Ahimza Nagasivam, Kerrie Stevenson, Robert W Aldridge, Fiona Stevenson, Sitira William, Rachel Burns
Journal: The Lancet (2023)
Untangling the association between COVID-19 health literacy, trust in the pandemic response, and mental distress, during the COVID-19 pandemic in Ireland: a repeated cross-sectional study
Authors: Julie Arnott, Maria Isabela Troya, Mary Joyce, Ali Khashan, Paul Corcoran, Zubair Kabir, Maire Connolly, Ivan Perry
Journal: The Lancet (2023)
Explaining differential socioeconomic effects in population health interventions: development and application of a new tool to classify intervention agentic demand
Authors: Kate Garrott, David Ogilvie, Jenna Panter, Amanda Sowden, Mark Petticrew, Catrin Penn-Jones, Campbell Foubister, Emma Lawlor, Erika Ikeda, Richard Patterson, Dolly Van Tulleken, Roxanne Armstrong-Moore, Gokulan Vethanayakam, Lorna Bo, Martin White, Jean Adams
Journal: The Lancet (2023)
Factors affecting the delivery of community-based salon interventions to prevent cardiovascular disease and breast cancer among ethnically diverse women in South London: a concept-mapping approach
Authors: Maham Zaman, Marjorie Lima de Vale, Clare Coultas, Louise Goff, Ashlyn Mernagh-iles, Veline L’Esperance, Alexis Karamanos, Salma Ayis, Vasa Ćurčin, Stevo Durbaba, Muriel Inyang, Mariam Molokhia, Seeromanie Harding
Journal: The Lancet (2023)
Autoimmune diseases and adverse pregnancy outcomes: an umbrella review
Authors: Megha Singh, Steven Wambua, Siang Ing Lee, Kelvin Okoth, Zhaonan Wang, Fathima Fazla, Ahamed Fayaz, Kelly-Ann Eastwood, Catherine Nelson-Piercy, Krishnarajah Nirantharakumar, Francesca Crowe
Journal: The Lancet (2023)
Determinants of lipid clinic referral and attendance in a multi-ethnic adult population in south London: a cross-sectional study
Authors: Aya Ayoub, Ralph K Akyea, Veline L’Esperance, Salma Ayis, Divya Parmar, Stevo Durbaba, Mark Fisher, Riyaz Patel, Seeromanie Harding, Anthony S Wierzbicki, Nadeem Qureshi, Mariam Molokhia
Journal: The Lancet (2023)
Interventions to improve oral health and related health behaviours of substance use, smoking, and diet in people with severe and multiple disadvantage: a systematic review of effectiveness and cost-effectiveness
Authors: Deepti A John, Laura J McGowan, Ryan P W Kenny, Emma C Joyes, Emma A Adams, Hosein Shabaninejad, Catherine Richmond, Fiona Beyer, David Landes, Richard G Watt, Falko F Sniehotta, Martha Paisi, Clare Bambra, Dawn Craig, Eileen Kaner, Sheena E Ramsay
Journal: The Lancet (2023)
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials
Authors: George R Thompson, Alex Soriano, Patrick M Honore, Matteo Bassetti, Oliver A Cornely, Marin Kollef, Bart Jan Kullberg, John Pullman, Maya Hites, Jesús Fortún, Juan P Horcajada, Anastasia Kotanidou, Anita F Das, Taylor Sandison, Jalal A Aram, Jose A Vazquez, Peter G Pappas
Journal: The Lancet Infectious Diseases (2023)

<h2>Summary</h2><h3>Background</h3> Rezafungin, a new US Food and Drug Administration-approved, long-acting echinocandin to treat candidaemia and invasive candidiasis, was efficacious with a similar safety profile to caspofungin in clinical trials. We conducted pooled analyses of the phase 2 STRIVE and phase 3 ReSTORE rezafungin trials. <h3>Methods</h3> ReSTORE was a multicentre, double-blind, double-dummy, randomised phase 3 trial conducted at 66 tertiary care centres in 15 countries. STRIVE was a multicentre, double-blind, double-dummy, randomised phase 2 trial conducted at 44 centres in 10 countries. Adults (≥18 years) with candidaemia or invasive candidiasis were treated with once-a-week intravenous rezafungin (400 mg and 200 mg) or once-a-day intravenous caspofungin (70 mg and 50 mg). Efficacy was evaluated in a pooled modified intent-to-treat (mITT) population. Primary efficacy endpoint was day 30 all-cause mortality (tested for non-inferiority with a pre-specified margin of 20%). Secondary efficacy endpoint was mycological response. Safety was also evaluated. The STRIVE and ReSTORE trials are registered with ClinicalTrials.gov, NCT02734862 and NCT03667690, and both studies are complete. <h3>Findings</h3> ReSTORE was conducted from Oct 12, 2018, to Oct 11, 2021, and STRIVE from July 26, 2016, to April 18, 2019. The mITT population, pooling the data from the two trials, comprised 139 patients for rezafungin and 155 patients for caspofungin. Day 30 all-cause mortality rates were comparable between groups (19% [26 of 139] for the rezafungin group and 19% [30 of 155] for the caspofungin group) and the upper bound of the 95% CI for the weighted treatment difference was below 10% (−1·5% [95% CI −10·7 to 7·7]). Mycological eradication occurred by day 5 in 102 (73%) of 139 rezafungin patients and 100 (65%) of 155 caspofungin patients (weighted treatment difference 10·0% [95% CI −0·3 to 20·4]). Safety profiles were similar across groups. <h3>Interpretation</h3> Rezafungin was non-inferior to caspofungin for all-cause mortality, with a potential early treatment benefit, possibly reflecting rezafungin's front-loaded dosing regimen. These findings are of clinical importance in fighting active and aggressive infections and reducing the morbidity and mortality caused by candidaemia and invasive candidiasis. <h3>Funding</h3> Melinta Therapeutics and Cidara Therapeutics.
Black Phosphorus as a Targeting PPAR‐γ Agonist to Reverse Chemoresistance in Patient‐derived Organoids, Mice, and Pancreatic Tumor Cells (Adv. Healthcare Mater. 29/2023)
Authors: Shengwei Jiang, Weihan Liu, Dan Shi, Huan Cheng, Tingwei Deng, Guoyong Chen, Li Ma, Xianbin Zhang, Peng Gong
Journal: Advanced Healthcare Materials (2023)
Reactive Oxygen Species‐Responsive Polymeric Prodrug Nanoparticles for Selective and Effective Treatment of Inflammatory Diseases (Adv. Healthcare Mater. 29/2023)
Authors: Yaming Zhang, Lu Liu, Tianyi Wang, Cong Mao, Pengfei Shan, Chak Sing Lau, Zhongyu Li, Weisheng Guo, Weiping Wang
Journal: Advanced Healthcare Materials (2023)
A Biomimetic Nanoplatform with Improved Inflammatory Targeting Behavior for ROS Scavenging‐Based Treatment of Ulcerative Colitis (Adv. Healthcare Mater. 29/2023)
Authors: Xiaofen Wang, Menglu Jiao, Fangzhen Tian, Xuan Lu, Huihuang Xiong, Fan Liu, Yiqun Wan, Xiaodong Zhang, Hao Wan
Journal: Advanced Healthcare Materials (2023)
Whole Model Path Planning‐Guided Multi‐Axis and Multi‐Material Printing of High‐Performance Intestinal Implantable Stent (Adv. Healthcare Mater. 29/2023)
Authors: Jiahang Wang, Jinjian Huang, Ze Li, Kang Chen, Huajian Ren, Xiuwen Wu, Jianan Ren, Zongan Li
Journal: Advanced Healthcare Materials (2023)
Combination Therapy with Resveratrol and Celastrol Using Folic Acid‐Functionalized Exosomes Enhances the Therapeutic Efficacy of Sepsis (Adv. Healthcare Mater. 29/2023)
Authors: Xue Zheng, Yujie Xing, Ke Sun, Hongzhen Jin, Wei Zhao, Fan Yu
Journal: Advanced Healthcare Materials (2023)
Redox Homeostasis Disruptors Based on Metal‐Phenolic Network Nanoparticles for Chemo/Chemodynamic Synergistic Tumor Therapy through Activating Apoptosis and Cuproptosis (Adv. Healthcare Mater. 29/2023)
Authors: Fan Zhao, Hongyan Yu, Liying Liang, Chen Wang, Dier Shi, Xiangyu Zhang, Yao Ying, Wei Cai, Wangchang Li, Juan Li, Jingwu Zheng, Liang Qiao, Shenglei Che, Jing Yu
Journal: Advanced Healthcare Materials (2023)
Ameliorating impaired cardiac function in myocardial infarction using exosome-loaded gallic-acid-containing polyurethane scaffolds
Authors: Ankita Das, Aman Nikhil, Parvaiz Ahmad Shiekh, Babita Yadav, Kumaravelu Jagavelu, Ashok Kumar
Journal: Bioactive Materials (2023)

Myocardial infarction (MI) can be tackled by implanting cardiac patches which provide mechanical support to the heart. However, most tissue-engineered scaffolds face difficulty in attenuating oxidative stress, maintaining mechanical stability, and regenerating damaged cardiomyocytes. Here, we fabricated elastic cryogels using polyurethane modified with antioxidant gallic acid in its backbone (PUGA) and further coated them with decellularized extracellular matrix (dECM) to improve adhesiveness, biocompatibility and hemocompatibility. The scaffold was functionalized with exosomes (EXO) isolated from adipose-derived stem cells having regenerative potential. PUGA-dECM + EXO was tested in a rat model with induced MI where echocardiography after 8 weeks of implantation showed significant recovery in treatment group. Histological analysis revealed a decrease in fibrosis after application of patch and promotion of angiogenesis with reduced oxidative stress was shown by immunostaining. Expression of cardiac tissue contractile function marker was also observed in treatment groups. Thus, the proposed biomaterial has a promising application to be utilized as a patch for cardiac regeneration. More detailed studies with larger animal species are needed for using these observations for specific applications.
NIR-II light triggered burst-release cascade nanoreactor for precise cancer chemotherapy
Authors: Yu-Jing Pan, Yang Zhang, Biao-Qi Chen, Yi Zhao, Jin-Yang Wang, Chang-Yong Li, Da-Gui Zhang, Ranjith Kumar Kankala, Shi-Bin Wang, Gang Liu, Ai-Zheng Chen
Journal: Bioactive Materials (2023)

The current strategy of co-delivering copper ions and disulfiram (DSF) to generate cytotoxic CuET faces limitations in achieving rapid and substantial CuET production, specifically in tumor lesions. To overcome this challenge, we introduce a novel burst-release cascade reactor composed of phase change materials (PCMs) encapsulating ultrasmall Cu2-xSe nanoparticles (NPs) and DSF (DSF/Cu2-xSe@PCM). Once triggered by second near-infrared (NIR-II) light irradiation, the reactor swiftly releases Cu2-xSe NPs and DSF, enabling catalytic reactions that lead to the rapid and massive production of Cu2-xSe-ET complexes, thereby achieving in situ chemotherapy. The mechanism of the burst reaction is due to the unique properties of ultrasmall Cu2-xSe NPs, including their small size, multiple defects, and high surface activity. These characteristics allow DSF to be directly reduced and chelated on the surface defect sites of Cu2-xSe, forming Cu2-xSe-ET complexes without the need for copper ion release. Additionally, Cu2-xSe-ET has demonstrated a similar (to CuET) anti-tumor activity through increased autophagy, but with even greater potency due to its unique two-dimensional-like structure. The light-triggered cascade of interlocking reactions, coupled with in situ explosive generation of tumor-suppressive substances mediated by the size and valence of Cu2-xSe, presents a promising approach for the development of innovative nanoplatforms in the field of precise tumor chemotherapy.